P1090 Grouping of intermediate risk factors in FIGO stage IB-IIA postoperative cervical cancer

2009 ◽  
Vol 107 ◽  
pp. S717-S717
Author(s):  
S. Ryu ◽  
S. Park ◽  
K. Kim ◽  
B. Kim ◽  
M. Kim ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Figo Stage ◽  
Intermediate Risk ◽  
Stage Ib

Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage IB–IIA cervical cancer

2008 ◽  
Vol 18 (5) ◽  
pp. 1027-1031 ◽  
Author(s):  
K.-B. Lee ◽  
J.-M. Lee ◽  
K.-D. Ki ◽  
S.-K. Lee ◽  
C.-Y. Park ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Adjuvant Chemotherapy ◽  
Tumor Size ◽  
Resection Margin ◽  
Figo Stage ◽  
Uterine Cervical Cancer ◽  
Intermediate Risk ◽  
Stromal Invasion ◽  
Stage Ib

The aim of this study was to compare the outcome of chemotherapy or radiation as adjuvant therapy for patients with FIGO stage IB–IIA cervical cancer and surgically confirmed intermediate risk factors. Data were collected from patients with uterine cervical cancer FIGO stage IB–IIA who had adjuvant chemotherapy following radical hysterectomy with pelvic lymph node dissection (RHLND, cases) or adjuvant radiotherapy following RHLND (controls). The study groups consisted of 38 cases and 42 controls. Adjuvant treatment was given to the patients with a combination of intermediate risk factors including deep stromal invasion (>50%), lymphvascular space invasion, large tumor size (3–6 cm), or close vaginal resection margin (<1 cm). Comparison of the cases with the controls revealed no significant differences in variables studied including median age (P= 0.18), stage distribution (P= 0.30), histologic subtype (P= 0.93), pathologic tumor size (P= 0.46), depth of the stromal invasion (P= 0.29), lymphvascular space invasion (P= 0.50), and close vaginal resection margin (P= 0.62). The difference in disease-free survival rates was not significant (P= 0.68). However, the overall survival analysis was incomplete due to the limited number of events available at the end of the study period. The findings of this study suggest that adjuvant chemotherapy in patients with FIGO stage IB–IIA uterine cervical cancer and surgically confirmed intermediate risk factors may be effective.

Preoperatively Assessable Clinical and Pathological Risk Factors for Parametrial Involvement in Surgically Treated FIGO Stage IB–IIA Cervical Cancer

2017 ◽  
Vol 27 (8) ◽  
pp. 1722-1728 ◽  
Author(s):  
Emel Canaz ◽  
Eser Sefik Ozyurek ◽  
Baki Erdem ◽  
Merve Aldikactioglu Talmac ◽  
Ipek Yildiz Ozaydin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Figo Stage ◽  
Stage Ib ◽  
Parametrial Involvement

scholarly journals Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery

2020 ◽  
Author(s):  
Xiaojing Zhang ◽  
Zunfu Lv ◽  
Xiaoxian Xu ◽  
Zhuomin Yin ◽  
hanmei Lou
Keyword(s):  
Cervical Cancer ◽  
Cox Regression ◽  
Adenosquamous Carcinoma ◽  
Risk Groups ◽  
Figo Stage ◽  
Chinese Patients ◽  
Survival Outcomes ◽  
Intermediate Risk ◽  
Stage Ib ◽  
Risk Patients

Abstract Background: To compare adenocarcinoma (AC) and adenosquamous carcinoma (ASC) prognoses in patients with FIGO stage IB–IIA cervical cancer who underwent radical hysterectomy. Methods. We performed a retrospective analysis of 240 patients with AC and 130 patients with ASC. Kaplan–Meier curves, Cox regression models, and log-rank tests were used for statistical analysis. Results: Patients with ASC had higher frequencies of lymphovascular space invasion (LVSI) and serum squamous cell carcinoma antigen (SCC-Ag) > 5 ng/ml (p=0.049 and p=0.013, respectively); moreover, they were much older (P=0.029) than patients with AC. There were no clinically significant differences in overall survival (OS) between the groups. When stratified into three risk groups based on clinicopathological features, survival outcomes did not differ between patients with AC and those with ASC in any risk group. Multivariate analysis showed that lymph node metastasis (LNM) was an independent risk factor for recurrence-free survival (RFS) and OS in patients with AC and in patients with ASC. Carcinoembryonic antigen (CEA) > 5 ng/ml and SCC-Ag > 5 ng/ml were independent predictors of RFS and OS in patients with AC. In addition, among those stratified as intermediate-risk, patients with ASC who received concurrent chemoradiotherapy (CCRT) had significantly better RFS and OS (P=0.036 and P=0.047, respectively). Conclusions: We did not find evidence to suggest that AC and ASC subtypes of cervical cancer were associated with different survival outcomes. CCRT is beneficial for survival in intermediate-risk patients with ASC, but not in those with AC. Serum tumour markers can assist in evaluating prognosis and in providing additional information for patient-tailored therapy for cervical AC.

scholarly journals Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery

2020 ◽  
Author(s):  
Xiaojing Zhang ◽  
Zunfu Lv ◽  
Xiaoxian Xu ◽  
Zhuomin Yin ◽  
hanmei Lou
Keyword(s):  
Cervical Cancer ◽  
Cox Regression ◽  
Adenosquamous Carcinoma ◽  
Risk Groups ◽  
Figo Stage ◽  
Chinese Patients ◽  
Survival Outcomes ◽  
Intermediate Risk ◽  
Stage Ib ◽  
Risk Patients

Abstract Background. To compare adenocarcinoma (AC) and adenosquamous carcinoma (ASC) prognoses in patients with FIGO stage IB–IIA cervical cancer who underwent radical hysterectomy.Methods. We performed a retrospective analysis of 240 patients with AC and 130 patients with ASC. Kaplan–Meier curves, Cox regression models, and log-rank tests were used for statistical analysis.Results. Patients with ASC had higher frequencies of lymphovascular space invasion (LVSI) and serum squamous cell carcinoma antigen (SCC-Ag) > 5 ng/ml (p=0.049 and p=0.013, respectively); moreover, they were much older (P=0.029) than patients with AC. There were no clinically significant differences in overall survival (OS) between the groups. When stratified into three risk groups based on clinicopathological features, survival outcomes did not differ between patients with AC and those with ASC in any risk group. Multivariate analysis showed that lymph node metastasis (LNM) was an independent risk factor for recurrence-free survival (RFS) and OS in patients with AC and in patients with ASC. Carcinoembryonic antigen (CEA) > 5 ng/ml and SCC-Ag > 5 ng/ml were independent predictors of RFS and OS in patients with AC. In addition, among those stratified as intermediate-risk, patients with ASC who received concurrent chemoradiotherapy (CCRT) had significantly better RFS and OS (P=0.036 and P=0.047, respectively). Conclusions. We did not find evidence to suggest that AC and ASC subtypes of cervical cancer were associated with different survival outcomes. CCRT is beneficial for survival in intermediate-risk patients with ASC, but not in those with AC. Serum tumour markers can assist in evaluating prognosis and in providing additional information for patient-tailored therapy for cervical AC.

Impact of the Addition of Concurrent Chemotherapy to Pelvic Radiotherapy in Surgically Treated Stage IB1-IIB Cervical Cancer Patients With Intermediate-Risk or High-Risk Factors: A 13-Year Experience

2013 ◽  
Vol 23 (3) ◽  
pp. 567-575 ◽  
Author(s):  
Mika Okazawa ◽  
Seiji Mabuchi ◽  
Fumiaki Isohashi ◽  
Osamu Suzuki ◽  
Yasuo Yoshioka ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Prognostic Factors ◽  
High Risk ◽  
Cancer Patients ◽  
Risk Group ◽  
Figo Stage ◽  
High Risk Group ◽  
Intermediate Risk ◽  
Stromal Invasion

ObjectivesTo identify groups of patients who derive clinical benefit from postoperative adjuvant concurrent chemoradiotherapy (CCRT), we retrospectively investigated the survival outcomes of surgically treated early-stage cervical cancer patients.MethodsWe reviewed the medical records of 316 patients with FIGO stage IB1-IIB cervical cancer who had been treated with adjuvant radiotherapy (RT) (n = 124, RT group) or adjuvant CCRT (n = 192, CCRT group) after radical hysterectomy between January 1996 and December 2009. Of these, 187 patients displayed high-risk prognostic factors (high-risk group), and 129 displayed intermediate-risk prognostic factors (intermediate-risk group). Sixty patients with 1 intermediate-risk prognostic factor who received no adjuvant therapy were also identified and used as controls (NFT group). Survival was calculated using the Kaplan-Meier method and compared using the log-rank test.ResultsIn the high-risk group, adjuvant CCRT was significantly superior to RT alone with regard to recurrence rate, progression-free survival (PFS), and overall survival. In the intermediate-risk group, CCRT was superior to RT with regard to recurrence rate and PFS in patents with 2 or more risk factors. Among the patients with only 1 intermediate-risk factor, although no survival benefit of CCRT over RT was observed, addition of adjuvant treatment resulted in significantly improved PFS compared with the NFT group in patients with deep stromal invasion (log-rank, P = 0.012).ConclusionsPostoperative CCRT improved the prognosis of FIGO stage IB1-IIB cervical cancer patients in the high-risk group and patients who displayed 2 or more intermediate-risk factors. Patients who displayed deep stromal invasion alone also derived clinical benefit from adjuvant treatment.

Sign in / Sign up

Export Citation Format

Share Document